Ideaya Biosciences (IDYA) Stock
Clinical stage biotech developing targeted cancer treatments. Here's the price, business snapshot, and what's worth knowing about Ideaya Biosciences in October 2026.
IDEAYA Biosciences (IDYA) is a clinical-stage biotechnology company focused on precision oncology, notably exploiting synthetic lethality to develop targeted cancer therapies. With a market capitalisation of about $2.56B, IDEAYA advances small molecules alongside biomarker strategies to identify patients most likely to benefit. The company is mainly pipeline-driven: value depends on clinical trial progress, regulatory milestones and partnership agreements rather than steady revenues. That profile brings both significant upside if trials succeed and pronounced downside if they do not — typical of early- to mid-stage biotechs. Investors should expect volatility, potential future fundraising or dilution, and long development timelines. This summary is general educational information only and not personal investment advice; investors should weigh clinical, regulatory and financial risks and consider suitability for their own risk tolerance before considering any position.
Ideaya Biosciences (IDYA) Stock Forecast
Analyst price target, next 12 months
$53.27
+42.6% vs today's $37.36
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Ideaya Biosciences have a consensus 12-month target of $53.27, above the current price of $37.36.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying IDEAYA Biosciences stock as it has good potential for growth.
Financial Health
IDEAYA Biosciences is generating solid revenue, cash flow, and has a strong book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical Pipeline Watch
Trial readouts and regulatory milestones strongly influence valuation, so keep an eye on upcoming clinical data — though results can be binary and volatile.
Synthetic Lethality Focus
IDEAYA's scientific approach targets cancer-specific genetic vulnerabilities, which may offer selective treatments but depends on complex biology translating to patients.
Partnering Potential
Collaborations with larger pharma can de‑risk development and expand resources, yet they typically hinge on compelling clinical progress and commercial viability.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
